CA3097667A1 - Methodes de diagnostic et de traitement basees sur la phosphorylation de tau specifique a un site - Google Patents

Methodes de diagnostic et de traitement basees sur la phosphorylation de tau specifique a un site Download PDF

Info

Publication number
CA3097667A1
CA3097667A1 CA3097667A CA3097667A CA3097667A1 CA 3097667 A1 CA3097667 A1 CA 3097667A1 CA 3097667 A CA3097667 A CA 3097667A CA 3097667 A CA3097667 A CA 3097667A CA 3097667 A1 CA3097667 A1 CA 3097667A1
Authority
CA
Canada
Prior art keywords
tau
phosphorylation
ratio
total
tau phosphorylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3097667A
Other languages
English (en)
Inventor
Nicolas BARTHELEMY
Randall John Bateman
Eric MCDADE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of CA3097667A1 publication Critical patent/CA3097667A1/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)

Abstract

La présente invention concerne des méthodes permettant de quantifier la phosphorylation de tau au niveau de résidus d'acides aminés spécifiques pour prédire le temps jusqu'à l'apparition d'une déficience cognitive légère due à la maladie d'Alzheimer, un stade de la maladie d'Alzheimer, des décisions de guidage de traitement, des sujets sélectionnés pour des essais cliniques, et pour évaluer l'efficacité clinique de certaines interventions thérapeutiques.
CA3097667A 2018-05-03 2019-05-03 Methodes de diagnostic et de traitement basees sur la phosphorylation de tau specifique a un site Pending CA3097667A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862666504P 2018-05-03 2018-05-03
US201862666509P 2018-05-03 2018-05-03
US62/666,504 2018-05-03
US62/666,509 2018-05-03
PCT/US2019/030725 WO2019213612A1 (fr) 2018-05-03 2019-05-03 Méthodes de diagnostic et de traitement basées sur la phosphorylation de tau spécifique à un site

Publications (1)

Publication Number Publication Date
CA3097667A1 true CA3097667A1 (fr) 2019-11-07

Family

ID=68386729

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3097667A Pending CA3097667A1 (fr) 2018-05-03 2019-05-03 Methodes de diagnostic et de traitement basees sur la phosphorylation de tau specifique a un site

Country Status (11)

Country Link
EP (1) EP3788062A4 (fr)
JP (1) JP7301394B2 (fr)
KR (1) KR20210004996A (fr)
CN (1) CN112166117A (fr)
AU (1) AU2019262220A1 (fr)
BR (1) BR112020021782A2 (fr)
CA (1) CA3097667A1 (fr)
MX (1) MX2020011458A (fr)
SG (1) SG11202010094TA (fr)
WO (1) WO2019213612A1 (fr)
ZA (1) ZA202006348B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3200832B1 (fr) 2014-09-30 2020-07-29 Washington University Mesures cinétiques de tau
KR20220062287A (ko) * 2019-08-13 2022-05-16 워싱턴 유니버시티 Mtbr 타우 아이소폼 검출 방법 및 이의 용도
AU2020344577A1 (en) * 2019-09-10 2022-03-31 Washington University Blood-based assay for diagnosing and treating based on site-specific tau phosphorylation
WO2021202777A1 (fr) * 2020-04-01 2021-10-07 Genentech, Inc. Utilisations de phosphosites de tau en tant que biomarqueurs pour la maladie d'alzheimer
EP4252243A2 (fr) 2020-11-30 2023-10-04 Enigma Biointelligence, Inc. Évaluation non invasive de la maladie d'alzheimer
CN112763636B (zh) * 2020-12-07 2022-04-19 佛山汉腾生物科技有限公司 肽图分析方法
US20230280357A1 (en) * 2021-03-31 2023-09-07 Washington University Csf phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies
WO2023288336A1 (fr) * 2021-07-16 2023-01-19 Washington University Procédés de détection des pentasaccharides et traitement et suivi de la maladie de stockage lysosomale
WO2023068173A1 (fr) * 2021-10-18 2023-04-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 BIOMARQUEUR POUR ÉVALUER L'ACCUMULATION D'AMYLOÏDE-β INTRACÉRÉBRALE
KR20240002809A (ko) * 2022-06-30 2024-01-08 광주과학기술원 타우 단백질 유래 인산화 펩타이드를 이용한 알츠하이머병 조기 진단, 단계 구분 및 뇌의 아밀로이드 베타 축적 판별 방법
KR20240002810A (ko) * 2022-06-30 2024-01-08 광주과학기술원 알츠하이머성 치매 관련 단백질 유래 인산화 펩타이드를 이용한 알츠하이머병 조기 진단, 단계 구분 및 뇌의 아밀로이드 베타 축적 판별 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA91683C2 (ru) * 2004-07-30 2010-08-25 Ринат Нейросаенз Корп. Антитела, направленные против бета-амилоидного пептида, и способы их применения
WO2008140639A2 (fr) * 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarqueurs et dosages pour la maladie d'alzheimer
WO2010011506A2 (fr) * 2008-07-23 2010-01-28 The Washington University Facteurs de risque et cible thérapeutique pour des troubles neurodégénératifs
FR2963791B1 (fr) * 2010-08-11 2012-09-21 Assist Publ Hopitaux De Paris Methode de diagnostic des maladies neurodegeneratives
SG10201703771WA (en) * 2011-09-19 2017-06-29 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
MX354662B (es) * 2011-10-07 2018-03-14 Ac Immune Sa Anticuerpos fosfoespecificos que reconocen la tau.
EP2787349A1 (fr) * 2013-04-03 2014-10-08 Affiris AG Procédé pour la détection d'anticorps Aß-spécifiques dans un échantillon biologique
TWI788704B (zh) * 2013-10-24 2023-01-01 美商納諾索米克斯公司 分析個體樣品之方法
ES2848376T3 (es) * 2014-11-19 2021-08-09 Axon Neuroscience Se Anticuerpos de tau humanizados en la enfermedad de Alzheimer
US11698378B2 (en) * 2015-09-25 2023-07-11 Children's Medical Center Corporation Methods and compositions for tauopathy diagnosis and treatment

Also Published As

Publication number Publication date
ZA202006348B (en) 2022-01-26
AU2019262220A8 (en) 2020-12-10
JP7301394B2 (ja) 2023-07-03
BR112020021782A2 (pt) 2021-02-23
MX2020011458A (es) 2020-12-07
EP3788062A1 (fr) 2021-03-10
CN112166117A (zh) 2021-01-01
AU2019262220A1 (en) 2020-11-12
SG11202010094TA (en) 2020-11-27
EP3788062A4 (fr) 2022-02-16
WO2019213612A1 (fr) 2019-11-07
KR20210004996A (ko) 2021-01-13
JP2021523357A (ja) 2021-09-02

Similar Documents

Publication Publication Date Title
JP7301394B2 (ja) 部位特異的タウリン酸化に基づく診断法及び治療方法
Barthélemy et al. Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer’s disease
US11402392B2 (en) Methods of treating based on site-specific tau phosphorylation
US20220299527A1 (en) Methods to detect mtbr tau isoforms and use thereof
US20230017557A1 (en) Blood-based assay for diagnosing and treating based on site-specific tau phosphorylation
WO2024044637A2 (fr) Anticorps anti-tau mtbr et méthodes de détection de fragments clivés de tau et leurs utilisations
US20230280357A1 (en) Csf phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies
CA3206077A1 (fr) Methodes de detection d'especes de tau dans le lcr comprenant le stade et la progression de la maladie d'alzheimer et leur utilisation
CN117355750A (zh) 检测阿尔茨海默病阶段和进展的csf tau物质的方法及其用途
WO2024107745A1 (fr) Procédés de détection de mtbr-tau de lcr et leurs utilisations
WO2023220276A1 (fr) PROCÉDÉS DE DÉTECTION DE PROTÉOFORMES Aβ ET LEUR UTILISATION

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240501